Archive | November, 2014

Life Science Nation and FreeMind Group Align In San Francisco for Early Stage Fundraising Executives

26 Nov

By Dennis Ford, Founder & CEO, LSN

Dennis bookToday, Life Science Nation (LSN) accelerates the funding of early stage life science firms via a sourcing platform for private investment, making CEOs more efficient in their capital raising efforts. The FreeMind Group (FMG) specializes in assisting life science organizations secure non-dilutive funding from US Federal Agencies and Private Foundations. LSN and FMG are experts in early stage private and non-dilutive funding respectively, and this complementary expertise fully supports the early stage financing needs of life science entrepreneurs.  As both of these financing sources are vital to early-stage financing, CEOs benefit from understanding both domains:  LSN’s 10 categories of private early stage and FMG’s governmental non-dilutive funding.

LSN and FMG have been working side by side for years, and recently saw that combining both pools of attendees at their respective conferences could transform each from a one-day event into a two-day conference offering dynamic partnering and compelling financing content to the early-stage CEOs visiting San Francisco during the JP Morgan Healthcare Conference.

Dennis Ford, CEO, LSN, stated “FreeMind and LSN give scientist entrepreneurs a 360 degree view of all the funding options available today.  Both the private and governmental capital landscape has morphed over recent years and I think this is a fabulous opportunity to help early stage CEOs get up to speed on both financing options. A savvy entrepreneur will go after all the capital available to them, both non-dilutive and private.  Indeed, most early stage companies already have a hybrid of each type of funding.  It’s part of the early stage gestalt.”

Ram May-Ran, Managing Partner, FMG, explained “Raising capital is fundamentally a numbers game.  Each financing option needs to be thoroughly explored, and that means both private and non-dilutive.”  Ram went on to say that many government funders offer matching funds for private capital brought into a company.  “It makes total sense for the CEOs to investigate and become knowledgeable on all the funding alternatives as this can greatly reduce the time spent raising capital.”

LSN owns and operates the Redefining Early Stage Investments (RESI) conference series.  The next RESI will be held on January 13th in San Francisco, at the Marines’ Memorial Club and Hotel. FMG owns and operates the Non-Dilutive Funding Summit, which will be held on January 14th in San Francisco at the Nikko Hotel. By virtually connecting these two events, attendees at LSN’s RESI will automatically be registered for FMG’s Non-Dilutive Funding Summit, and in turn Summit attendees will be able to get a discount coupon to register for RESI.  Executives from each firm agree that this may become an ongoing relationship, as creating these venues for partnering and fundraising can support a groundswell to aid in the commercialization of science.

For more information on LSN and RESI:

For more information on FMG and Non-Dilutive Funding Summit:

A Thanksgiving Mandate Cornucopia

26 Nov

By Lucy Parkinson, Senior Research Manager, LSN

lucy 10*10Here at LSN, we’re getting ready to go home for Thanksgiving.  But first, we’d like to thank all our readers, supporters and friends across the global life science industry.  We wouldn’t be here without you.

In the spirit of the season, LSN Research welcomes you to the table to share the mandates we’ve gathered from our recent conversations with investors across the world.  This cornucopia of investors are from 6 different nations, and cover every niche of the life science sector – from agriculture to therapeutics to devices to healthcare IT.

Click on the mandates below to see what’s cooking in the rest of the world

  1. Private Equity Firm Seeks AgBio and Sustainable Bio Opportunities
  2. Early Stage VC Seeks Healthcare IT Opportunities
  3. Global Firm With Patient-Centric Strategy Invests In Oncology, Cardiovascular, Anti-infectives, CNS/pain, and Women’s Health
  4. Taiwan-based VC Investing In Innovative Early-Stage Medtech 
  5. South American Corporate VC Interested in Orphan Drugs
  6. UK-based Fund Group Seeks Medical Devices, Diagnostics, Lab Equipment, and Healthcare IT
  7. Cross-Border VC Looking At Healthcare Technology for Emerging Markets 
  8. Global Health Organization Funds Diagnostics, Vaccines and Women’s Health
  9. European PE Invests in Drug Development, Diagnostics, and Medical Devices
  10. Dutch Firm Investing In Medtech, Healthcare IT, and Biotech R&D Services

Hot Life Science Investor Mandate 1: Private Equity Firm Seeks AgBio and Sustainable Bio Opportunities

26 Nov

A venture capital and private equity firm based in California makes equity allocations in advanced biotechnologies such as synthetic biology. The firm is currently seeking opportunities globally.

The firm manages a fund that identifies compelling investment strategies in/around advanced biotechnologies. The fund focuses on scalable, portable and sustainable technologies within high human-imperative sectors such as agriculture-food, energy-resources, industrial chemicals-materials, water-environment, and defense-space. Medical and healthcare-related technology is not of interest at this point. When it comes to development phases, the fund is stage-agnostic and considers from seed and venture stage projects to on-market projects.

If you are interested in more information about this investor and other investors tracked by LSN, please email

%d bloggers like this: